{"blog": [], "keywords": [{"value": "Hepatitis", "name": "subject", "rank": "1", "is_major": "Y"}, {"value": "Gilead Sciences Inc", "name": "organizations", "rank": "2", "is_major": "Y"}, {"value": "Sovaldi (Drug)", "name": "subject", "rank": "3", "is_major": "Y"}, {"value": "Inventions and Patents", "name": "subject", "rank": "4", "is_major": "Y"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "5", "is_major": "Y"}, {"value": "Argentina", "name": "glocations", "rank": "6", "is_major": "N"}, {"value": "Brazil", "name": "glocations", "rank": "7", "is_major": "N"}, {"value": "China", "name": "glocations", "rank": "8", "is_major": "N"}, {"value": "Russia", "name": "glocations", "rank": "9", "is_major": "N"}, {"value": "Ukraine", "name": "glocations", "rank": "10", "is_major": "N"}], "web_url": "http://www.nytimes.com/2015/05/20/business/high-cost-of-hepatitis-c-drug-prompts-a-call-to-void-its-patents.html", "document_type": "article", "byline": {"person": [{"lastname": "POLLACK", "firstname": "Andrew", "role": "reported", "organization": "", "rank": 1}], "original": "By ANDREW POLLACK"}, "type_of_material": "News", "multimedia": [{"url": "images/2015/05/20/business/20GILEAD/20GILEAD-thumbWide.jpg", "legacy": {"wide": "images/2015/05/20/business/20GILEAD/20GILEAD-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2015/05/20/business/20GILEAD/20GILEAD-articleLarge.jpg", "legacy": {"xlarge": "images/2015/05/20/business/20GILEAD/20GILEAD-articleLarge.jpg", "xlargeheight": "480", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 480}, {"url": "images/2015/05/20/business/20GILEAD/20GILEAD-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/05/20/business/20GILEAD/20GILEAD-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "905", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "A New York group is expected to announce Wednesday that it has filed challenges to patents on Sovaldi in Argentina, Brazil, China, Russia and Ukraine.", "pub_date": "2015-05-20T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "High Cost of Hepatitis C Drug Prompts a Call to Void Its Patents", "main": "High Cost of Sovaldi Hepatitis C Drug Prompts a Call to Void Its Patents"}, "print_page": "3", "snippet": "A New York group is expected to announce Wednesday that it has filed challenges to patents on Sovaldi in Argentina, Brazil, China, Russia and Ukraine.", "_id": "555bdca338f0d82290bae66c", "slideshow_credits": null, "abstract": "Patient activist groups in Argentina, Brazil, China, Russia and Ukraine will file challenges seeking to void patents for Gilead Sciences blockbuster hepatitis C drug Sovaldi; argue that $84,000 price tag for course of treatment is prohibitive; actions are sign that controversy surrounding the drug in United States has spread abroad."}